$EPZM News
Last published 2y ago
- 2y agoEPZMApproval of Tazverik, Nda #211723 (Labeling)FDA Approved DrugsApproval Date: 08/13/2024; Drug Name: Tazverik, Nda #211723; Active Ingredients: TAZEMETOSTAT HYDROBROMIDE; Company: Epizyme Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 211723
- 3y agoEPZMTazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma - NCT05618366ClinicalTrials.govMaximum-tolerated dose (MTD) determination (Part 1), Number of participants who experience dose-limiting toxicities (DLTs), Number of participants who experience adverse events (AEs), from baseline to 30 days after the last dose of study drug, as assessed by CTCAE v5.0, (and 7 more...)
- 4y agoEPZMA Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer - NCT05567679ClinicalTrials.govIncidence of adverse events, serious adverse events, and treatment-related adverse events., Proportion of patients able to undergo surgery, Proportion of patients with Grade 3 or above treatment related adverse events, (and 2 more...)
- 4y agoEPZMEpizyme Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness WireTAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company's Novel, First-in-Class, Oral SETD2 Inhibitor Merger
- 4y agoCNVYEPZMOBCIRDUSMoore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law FirmPR NewswireNEW YORK, July 6, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to share
- 4y agoAXSMDTILEPZMNRSN+1Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027PR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 28, 2022 /PRNewswire/ -- Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors such as the i
- 4y agoEPZMEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual MeetingBusiness WireUpdated Activity Data from Phase 1b Portion of the Study Shows Continued Improvement in Both Objective and Complete Response Rates Update Includes Response Data for Sub-Group of Patients Who Are Rituximab-Refractory and with POD24 Epizyme, Inc. (N
- 4y agoEPZMEpizyme To Participate in H.C. Wainwright Global Investment ConferenceBusiness WireEpizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executiv
- 4y agoEPZMEpizyme Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness WireTAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epiz
- 4y agoEPZMEpizyme Announces Date of First Quarter 2022 Financial ResultsBusiness WireEpizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call t
- 4y agoEPZMEpizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEpizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that the Company has granted equity awards to
- 4y agoEPZMEpizyme Announces Executive Appointment and Provides Tazemetostat Clinical UpdateBusiness WireAppointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R2 Epizyme (NASDAQ:EPZM), a fully integrated,
- 4y agoEPZMEpizyme to Participate in Upcoming Healthcare Conferences in MarchBusiness WireEpizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced its participation in two investor conferences in March. Cowen
- 4y agoEPZMEpizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateBusiness WireTAZVERIK® (tazemetostat) Net Product Revenue of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021 $85 Million in Gross Proceeds Raised in January 2022 Public Offering, Combined with Recent Expense Reductions Announced Today, Extends Cash Runw
- 4y agoEPZMEpizyme Announces Date of Fourth Quarter and Full Year 2021 Financial ResultsBusiness WireEpizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its fourth quarter and full year 2021 fin
- 4y agoEPZMEpizyme Announces Pricing of Public Offering of Common StockBusiness WireEpizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced the pricing of an underwritten public offering of 56,666,667 shares of its common stock at
- 4y agoEPZMEpizyme Announces Proposed Public Offering of Common StockBusiness WireEpizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offe
- 4y agoEPZMEpizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial UpdatesBusiness Wire-- Preliminary TAZVERIK® (tazemetostat) Net Product Revenue Expected to be Between $11.2-11.7 Million and Between $30.6-31.1 Million for 4Q 2021 and Full-Year 2021, Respectively; Preliminary TAZVERIK Commercial Net Sales Expected to be Between $7.0-7.5
- 4y agoEPZMEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual MeetingBusiness WireEpizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today presented updated safety and activity data from the Phase 1b portion o
- 4y agoEPZMEpizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company's SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual MeetingBusiness WireEpizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today shared preclinical data and the Phase 1/1b trial design for EZM0414, t
- 4y agoEPZMEpizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual MeetingBusiness WireEpizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced that new data from across its oncology portfolio will be pre
- 4y agoEPZMEpizyme Announces Updates to Its Board of DirectorsBusiness WireEpizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced two appointments to the Company's Board of Directors: clinical oncology executive, Roy A. B
- 5y agoEPZMEpizyme to Participate in Jefferies London Healthcare ConferenceBusiness WireEpizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Grant Bogle, President and Chief Executive Officer of Epizyme, will present at the J
- 5y agoEPZMEpizyme Reports Third Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire-- TAZVERIK® (tazemetostat) Net Product Revenues of $5.2 Million; End User Demand Grew 22% -- -- Received $25 Million Upfront Payment from HUTCHMED License Agreement -- -- SYMPHONY-1 (EZH-302) Preparing for Phase 3 Initiation; SETD2 Phase 1/1b St
- 5y agoEPZMEpizyme, inc (EPZM) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsEPZM earnings call for the period ending September 30, 2021.
- 5y agoEPZMEpizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEpizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the Company approved the grant of equity awards to a new employee with a grant date of Novem
- 5y agoEPZMEpizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414Business WireEpizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EZM0
- 5y agoEPZMEpizyme Announces Date of Third Quarter 2021 Financial ResultsBusiness WireEpizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its third quarter 2021 financial results
- 5y agoEPZMEpizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision MakingBusiness WireEpizyme today announced the launch of In My Blood, an online resource designed to empower people living with follicular lymphoma to partner with their healthcare providers and play a proactive role in treatment decision-making based on where they
- 5y agoEPZMEpizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEpizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the Company approved the grant of equity awards to a new employee with a grant date of Octob
- 5y agoEPZMEpizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual CongressBusiness WireTwo Poster Presentations for Tazemetostat, a Methyltransferase Inhibitor, in Metastatic Castration-Resistant Prostate Cancer and in Combinations in Patients with Solid Tumors Epizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage bioph
- 5y agoEPZMGlaxoSmithKline LLC vs Epizyme, Inc. - AIA Trial, Settlement after InstitutionUS Patent Trial and Appeal Board
- 5y agoEPZMPhase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation - NCT05023655ClinicalTrials.govOverall Response Rate, Disease Control Rate
- 5y agoEPZMEpizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEpizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the Company approved the grant of equity awards to two new employees with a grant date of Au
- 5y agoEPZMEpizyme Announces CEO SuccessionBusiness WireCurrent Chief Executive Officer, Robert Bazemore, to Step Down; Current Board Member, Grant Bogle, Named Incoming CEO Epizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenet
- 5y agoEPZMEpizyme Reports Second Quarter 2021 Financial Results and Provides Business UpdateBusiness WireTotal Revenue of $13.0 Million in 2Q 2021; TAZVERIK® Net Product Revenues of $8.0 Million Revised Commercial Strategy and Operating Plan to Accelerate Adoption of TAZVERIK® and Focus Investment on Important Value-Driving Programs IND Clearance
- 5y agoEPZMEpizyme, inc (EPZM) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsEPZM earnings call for the period ending June 30, 2021.
- 5y agoEPZMHCMHUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater ChinaGlobeNewswireCollaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED's novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payment
- 5y agoEPZMHCMEpizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater ChinaBusiness WireCollaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED's novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone paymen
- 5y agoEPZMEpizyme Announces Date of Second Quarter 2021 Financial ResultsBusiness WireEpizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its second quarter 2021 financial results
- 5y agoDGXEPZMEpizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma PatientsBusiness WireEZH2Now Testing Program is first of its kind to offer national single gene testing for EZH2 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today launched the
- 5y agoEPZMEpizyme to Participate in Jefferies Virtual Healthcare ConferenceBusiness WireEpizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, President and Chief Executive Officer, will participate in a fireside chat
- 5y agoEPZMEpizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in JuneBusiness WireOral Presentation of Preclinical Data on Inhibition of SETD2, a Histone Methyltransferase, in Multiple Myeloma to be Presented at the European Hematology Association (EHA) Congress Poster Presentation for Tazemetostat, a Methyltransferase Inhibito
- 5y agoAMCARQTEPZMEVFM+1Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics?PR NewswireNEW YORK, May 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EPZM, AMC, EVFM, NOK, and ARQT. To se
- 5y agoEPZMEpizyme Inc (EPZM) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsEPZM earnings call for the period ending March 31, 2021.
- 5y agoEPZMEpizyme Provides Business Update and Reports First Quarter 2021 Financial ResultsBusiness WireTotal Revenue of $7.6 Million for 1Q 2021; TAZVERIK® Net Product Revenues of $6.2 Million Ongoing TAZVERIK Clinical Trials in both Follicular Lymphoma and Prostate Cancer Demonstrate Encouraging Preliminary Safety and Activity Data Investigationa
- 5y agoEPZMEpizyme Announces Date of First Quarter 2021 Financial ResultsBusiness WireEpizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2021 financ
- 5y agoEPZMPFEPhase Ia/Ib Talazoparib + Tazemetostat for mCRPC - NCT04846478ClinicalTrials.govRate of Dose Limiting Toxicity (DLT), Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0, Overall response rate (ORR)
- 5y agoEPZMNew patent application published for: Combination Therapy for Treating CancerUS Patent Applications (USPTO)
- 5y agoEPZMNew patent application published for: Method for Treating CancerUS Patent Applications (USPTO)( 1 of 1 )